Brian Walker

High Impact

Manager, Controls and Grid-Edge Decarbonization

UA Little Rock

Also affiliated: University College Dublin (2004); University of Central Florida (2008); Queen's University Belfast (1976–2022); Indiana University Health (2021); Belfast Health and Social Care Trust (2010); Monsanto (United States) (1999); Dalhousie University (1991); Girls Incorporated (1999); Royal Marsden NHS Foundation Trust (2016); United States Department of Energy (2019–2022); Defence Science and Technology Laboratory (2009); Pacific Northwest National Laboratory (2022); Royal College of Surgeons in Ireland (1998–2000); University of Miami (2025); University of Alberta (1992–2018); National University of Ireland, Maynooth (1993); University of California, Los Angeles (2019); Stranmillis University College (1993); National University of Ireland (1971–1999); Universität Innsbruck (2008); SUNY Upstate Medical University (2025); Queen's University (1998–2008); Cornell University (1946–2005); University of Cambridge (2012–2015); Musgrave Park Hospital (1994); Oxford Research Group (2022); Oxford University Press (United Kingdom) (1996); Department of Agriculture and Rural Development (2000); PENTA Foundation (1999); Vehicle Technologies Office (2019); Queens University (1986–2014); Government of British Columbia (1993); St Olav's University Hospital (1989); Friedrich Miescher Institute (1985); Indiana Cancer Consortium (2021); Wisdom Health (United States) (1996); Ministry of Agriculture (1993); Sylvester Comprehensive Cancer Center (2025); Indiana University Melvin and Bren Simon Comprehensive Cancer Center (2021); Indiana University – Purdue University Indianapolis (2021); Massachusetts Institute of Technology (2009–2012); Rice University (1978); Miami University (2025); Friedrich Miescher Institute (1986–1988)

Staff Researcher

43 h-index 486 pubs 7,695 cited

Research Areas

Biomedical Subjects

Links

ORCID Research Group

OverviewAI-generated summary

Brian Walker's research interests encompass the development of novel inhibitors and activity-based probes targeting serine proteases, with applications in understanding and potentially treating diseases like cystic fibrosis. His work on protease signaling has shown promise in improving mucociliary function in airways affected by this condition. Walker has also investigated dehydrogenative conversions of aldehydes and amines to amides using nickel(II) pincer complexes and explored solvent-free, microwave-assisted synthesis methods for imidazole and pyrazole derivatives.

Further contributing to health sciences, Walker has been involved in creating engineered cell line imaging assays designed to differentiate pathogenic from non-pathogenic bacteria. His research has also touched upon the definition of high-risk in multiple myeloma. With an h-index of 43, 486 total publications, and over 7,673 citations, Walker is recognized as a highly cited researcher. He leads a research group and collaborates with colleagues at the University of Arkansas at Little Rock, including Melinda J. McAfee, J. L. Pack, Peter Szwedo, and Karie Sanford.

Metrics

h-index: 43
Publications: 486
Citations: 7,695

Selected Publications

Solvent-Free and Microwave-Assisted Synthesis Enables Formation of Imidazole and Pyrazole Derivatives Through Epoxide Ring Opening (2025)

1 citation DOI OpenAlex
Dehydrogenative Conversions of Aldehydes and Amines to Amides Catalyzed by a Nickel(II) Pincer Complex (2023)

Catalysts 7 citations DOI OpenAlex
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death (2019)

Nature Communications 134 citations DOI OpenAlex